Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.

Study at a glance

Characteristics	Case study Case report Peer reviewed
Sample size	1
Population	A depressed patient
Intervention	Ketamine
Topics	Esketamine Ketamine
Key findings	Peripheral mTOR activation changed in parallel with the patient's clinical response to ketamine, suggesting it may be a useful biomarker for monitoring treatment response in depression.

Other case reports and case series on ketamine, most cited first.

Study	Year	Design	Participants
The destruction of the lower urinary tract by ketamine abuse: a new syndrome? Young recreational abusers of street-ketamine in Hong Kong referred to urology units	2008	Retrospective case series	n = 59
Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. A patient with treatment-resistant depression and comorbid generalized anxiety...	2025	Case report	n = 1
Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions Chronic and treatment-resistant eating disorder patients	1998	Case series	n = 15
Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series Four depressed patients taking standard antidepressants	2009	Case series	n = 4
A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression Patients with enduring eating disorders and treatment-resistant depression	2021	Case series	n = 4

and 12 more in the library